AbbVie Inc. (ABBV)

64.43
NYSE : Health Technology
Prev Close 62.98
Day Low/High 63.07 / 64.81
52 Wk Low/High 62.66 / 100.23
Avg Volume 9.97M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 93.11B
EPS 3.70
P/E Ratio 22.41
Div & Yield 4.28 (6.57%)
Wall Street Weighs In on Athenahealth's Strategic Options

Wall Street Weighs In on Athenahealth's Strategic Options

Elliott's previous successes in the healthcare space bode well for its chances at athena.

AbbVie Stock Lower on Humira Patent Ruling

AbbVie Stock Lower on Humira Patent Ruling

The drug is responsible for more than 60% of AbbVie's top line.

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on AbbVie, Broadcom, Enbridge Energy Partners, and Commercial Vehicle Group.

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Jim Cramer says investors are migrating toward sectors likely to have the biggest upside in the second half.

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Cramer shares his views on which is better: Amazon or Alphabet, and discusses the domino effect when oil falls.

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Jim Cramer says this market is strong enough to withstand falling oil prices and a tax plan that will face a lot of obstacles.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.

AbbVie Is Flexing Its Abs

AbbVie Is Flexing Its Abs

ABBV is now set up well for more upside.

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks Turn Mixed in Face of Crude Oil Slump

Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock Futures Higher as Positive Earnings Offset Weaker Durable Goods Orders

Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on EQT Midstream Partners, AbbVie, Blackstone Group, and Core Civic.

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Dividend Stock Advisor Is Becoming Income Seeker

Subscribers to Dividend Stock Advisor will now receive Income Seeker, our newest premium product.

Must-Own Dividend Dates for April

Mark your calendars!

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.

TheStreet Quant Rating: B- (Buy)